DIVALPROEX SODIUM
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
| Metabolism | Extensively metabolized in the liver via glucuronidation (50%), beta-oxidation (40%), and CYP-mediated oxidation (10%, including CYP2C9 and CYP2A6). |
| Excretion | Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible. |
| Half-life | 9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations. |
| Protein binding | 90-95% (primarily to albumin); concentration-dependent, decreased in uremia or hypoalbuminemia. |
| Volume of Distribution | 0.13-0.23 L/kg (total body water); low Vd indicates limited extravascular distribution. |
| Bioavailability | Oral (delayed-release): ~90%; oral (extended-release): ~85-90%; intravenous: 100%. |
| Onset of Action | Oral (immediate-release): 1-4 hours; oral (delayed-release): 3-5 hours; intravenous: within minutes; clinical antiepileptic effect may take several days to weeks. |
| Duration of Action | Dosing interval: every 6-12 hours; clinical effects persist for up to 12 hours with immediate-release and longer with extended-release; continuous therapeutic effect requires regular dosing. |
| Molecular Weight | 144.21 |
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No specific dose adjustment for renal impairment; use with caution due to protein binding displacement. For anuria/oliguria, reduce dose by 25-50%. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh Class C). In mild-to-moderate (Child-Pugh A/B), reduce dose by 50% and monitor liver function and ammonia levels. |
| Pediatric use | Initial 10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; usual 30-60 mg/kg/day. Maximum 60 mg/kg/day. Extended-release not recommended for children <10 years. |
| Geriatric use | Start at lower end of dosing range (e.g., 10-15 mg/kg/day); increase slowly; monitor for adverse effects (tremor, weight gain, sedation). Clearance may be reduced; consider dose reduction by 20-25%. |
| 1st trimester | High risk of neural tube defects and other congenital malformations (e.g., cardiac defects), especially with doses ≥1000 mg/day. Valproate is contraindicated in pregnancy unless no alternative, with strict folate supplementation and daily doses <1000 mg. |
| 2nd trimester | Continued risk of structural anomalies; also potential for neurodevelopmental deficits in the child after in utero exposure. |
| 3rd trimester | Risk of hemorrhagic complications in neonate due to decreased vitamin K-dependent clotting factors; also risk of withdrawal symptoms (e.g., irritability, feeding difficulties) after birth. |
Clinical note
CYP450 enzyme inducers may decrease levels Can cause severe hepatotoxicity and teratogenic effects including neural tube defects.
| Placental transfer | Extensively crosses the placenta; fetal serum concentrations are 1–2 times higher than maternal levels due to active transport and protein binding differences. |
| Breastfeeding |
■ FDA Black Box Warning
Hepatotoxicity, including fatal hepatic failure, particularly in children under 2 years and patients with mitochondrial disease. Pancreatitis, including fatal hemorrhagic cases.
| Common Effects | Headache Injection site pain Injection site allergic reaction Abdominal pain Abdominal cramp Nausea Ovarian hyperstimulation syndrome |
| Serious Effects |
Known hypersensitivity to divalproex sodium or any componentAcute or chronic hepatitisSignificant hepatic dysfunction (e.g., severe hepatitis, cirrhosis)Known mitochondrial disease caused by POLG mutations (e.g., Alpers-Huttenlocher syndrome)Urea cycle disorders (e.g., ornithine transcarbamylase deficiency)
| Precautions | Hepatotoxicity, pancreatitis, teratogenicity (neural tube defects), thrombocytopenia, hyperammonemic encephalopathy, hypothermia, multi-organ hypersensitivity reaction, suicidal ideation, and drug interactions (e.g., lamotrigine, warfarin). |
Loading safety data…
| Divalproex sodium is excreted into breast milk at low concentrations (approximately 1–10% of maternal serum levels). While generally considered compatible with breastfeeding, monitor the infant for potential adverse effects such as sedation, thrombocytopenia, and hepatic dysfunction. Use with caution in mothers with high doses or hepatic impairment. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Divalproex sodium is a known human teratogen. First trimester exposure is associated with a 3-5% risk of neural tube defects (spina bifida), as well as facial clefts, cardiac defects, and hypospadias. Second and third trimester exposure may increase risks of neurodevelopmental delay, autism spectrum disorder, and lowered IQ. Dose-dependent risk; avoid use if possible. |
| Fetal Monitoring | Monitor valproate serum concentrations (therapeutic range 50-100 mcg/mL) and adjust dose to maintain seizure control. Fetal ultrasound for neural tube defects at 16-18 weeks, echocardiography at 18-22 weeks. Postnatal neurodevelopmental assessment. Maternal liver function tests and complete blood count monthly due to risk of hepatotoxicity and thrombocytopenia. |
| Fertility Effects | Divalproex sodium has no direct adverse effect on fertility. However, it may cause polycystic ovary syndrome (PCOS)-like symptoms in women, including menstrual irregularities, anovulation, and hyperandrogenism, potentially impairing fertility. These effects are reversible upon dose reduction or discontinuation. |
| Food/Dietary |
| Take with food to reduce GI upset. Avoid alcohol. There is no clinically significant interaction with specific foods; however, valproic acid absorption may be slightly delayed with high-fat meals but not dose adjustment needed. |
| Clinical Pearls | Divalproex sodium is a valproate compound with enteric coating to reduce GI irritation. Monitor liver function tests and ammonia levels, especially in patients with suspected urea cycle disorders. Use with caution in women of childbearing potential due to teratogenicity (neural tube defects). Therapeutic range for total valproic acid is 50-100 mcg/mL. Avoid use in patients with mitochondrial disorders due to risk of hepatotoxicity. |
| Patient Advice | Take with food to minimize stomach upset; do not crush or chew tablets. · Report any signs of liver problems: yellowing of skin/eyes, dark urine, persistent nausea/vomiting. · Use effective contraception if you are a woman of childbearing age; discuss pregnancy risks. · Do not stop suddenly as this can trigger seizures; follow dosage adjustments closely. · Avoid alcohol as it may worsen side effects like drowsiness and liver damage. · Contact doctor if you develop unusual bruising/bleeding, confusion, or worsening mood changes. |